Crossmark

Comparison of nivolumab plus ipilimumab with tyrosine kinase inhibitors as first-line therapies for metastatic renal-cell carcinoma: a multicenter retrospective study

Crossref DOI link: https://doi.org/10.1007/s10147-020-01797-5

Published Online: 2020-10-16

Published Print: 2021-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kido, Koichi

Hatakeyama, Shingo https://orcid.org/0000-0002-0026-4079
Numakura, Kazuyuki

Tanaka, Toshikazu

Oikawa, Masaaki

Noro, Daisuke

Hosogoe, Shogo

Narita, Shintaro

Inoue, Takamitsu

Yoneyama, Takahiro

Ito, Hiroyuki

Nishimura, Shoji

Hashimoto, Yasuhiro

Kawaguchi, Toshiaki

Habuchi, Tomonori

Ohyama, Chikara
Funding

Funding for this research was provided by:

Japan Society for the Promotion of Science (19H05556)

Japan Society for the Promotion of Science (20K09517)
License Information

Text and Data Mining valid from 2020-10-16

Version of Record valid from 2020-10-16
More Information

Article History

Received: 11 July 2020

Accepted: 23 September 2020

First Online: 16 October 2020

Compliance with ethical standards

:

: The authors have no conflicts of interest to declare except for Dr. Habuchi Tomonori. He received honoraria from Ono Pharmaceutical Company Ltd., Pfizer Inc., Novartis Pharmaceutical Company Ltd., and Merck & Company, Inc. He also received research funding from Ono Pharmaceutical Company Ltd., Pfizer Inc., and Merck & Company, Inc.

: Written consent was not required in exchange for public disclosure of study information (opt-out approach) in the case of retrospective and/or observational study using materials, such as the existing documentation.

: All authors agreed with the publication.

Document is current

Any future updates will be listed below